Contact Supplier

Contact Supplier

To get in touch with CBDepot s.r.o., simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    .

    GMP production of CBDepot group Cannabidiol as a pharma API

    products-servicesCBDepot s.r.o.
    May 28th 2021

    CBDepot has underlined its status at Europe’s leading manufacturer of ethical hemp-derived and cannabinoid-related products by fully certificating its Czech Republic production facilities for isolated and synthesized Cannabidiol (CBD) as an active pharmaceutical ingredients to full EU Good Manufacturing Practice (GMP) standards.

    GMP certified status is confirmed by the Czech National Competent Authority State Institute for Drug Control, which has issued a Manufacturer Certificate of GMP Compliance to CBDepot sister company CB21 Pharma, for its plant in Brno that specializes in production of trans-cannabidiol (trans-CBD) as an active substance. The certification has been filed with the EU’s EudraGMDP system.

    In-house GMP production 

    The certification allows CB21 Pharma to offer the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot.

    Since 2017, CBDepot has been offering isolated GMP CBD via third party contract manufacturing arrangement but has now brought production fully in-house from its new facility in Brno.

    The facility uses chemical synthesis to manufacture pharma grade synthesized (–)-trans-Cannabidiolum as well as isolating pure CBD distillate from cannabis sativa plants. Both are suitable as cGMP active substance for pharmaceutical use.

    Upgraded processes

    CBDepot is also submitting an Active Substance Master File and is implementing decarboxylation and distillation processes that will enable manufacture of full-spectrum GMP standard cannabinoid APIs for various pharmaceutical uses.

    CBDepot has released a full presentation from its Chief Sales Officer Boris Baňas explaining more about the legal status of cannabinoids in products for the EU market (see Resources).

    Resources

    Click on CBDepot group announces new EU GMP compliant manufacturing site for Cannabidiol APIs for further information.
    Click on Legal Status of Cannabinoids in end-user products on EU market to access presentation from CBDepot Chief Scientific Officer.
    Click on CBDepot Products to watch CBDepot video.

    GMP production of CBDepot group Cannabidiol as a pharma API

    CBDepot sister company CB21 Pharma uses chemical synthesis to manufacture pharma grade synthesized (–)-trans-Cannabidiol as a cGMP active substance for pharmaceutical use, as well as isolating CBD distillate from cannabis sativa plants

    Contact CBDepot s.r.o.

    Simply fill out the form below to contact CBDepot s.r.o. now.

    Send CBDepot s.r.o. a Message